Corline Biomedical specializes in advanced surface coating technologies aimed at enhancing medical devices and regenerative medicine applications. Their flagship product, Corline Heparin Surface Technology (CHS™), utilizes a unique macro-molecular heparin coating that has demonstrated superior performance across various medical devices. This technology is designed to provide antithrombotic and anti-inflammatory properties, significantly reducing the risks associated with blood clotting and inflammation during medical procedures. The company also offers CHC™ technology, which leverages the natural biomolecule heparin to improve localized concentrations without the systemic bleeding risks typically associated with heparin administration. This technology is supported by a robust portfolio of over 100 scientific publications, underscoring its efficacy and safety in clinical applications.

In the realm of regenerative medicine, Corline's Cytoparin™ product addresses critical challenges in islet transplantation for Type 1 diabetes patients. By acting as a protective barrier against immune responses and inflammation, Cytoparin™ enhances the survival of transplanted islet cells, aiming to improve transplant outcomes and reduce the need for multiple donors. This innovative approach not only seeks to establish a one-to-one donor-to-patient relationship but also extends to the development of artificial biopancreases, which are designed to regulate insulin production externally. Through these technologies, Corline Biomedical is making significant strides in both the medical device industry and regenerative medicine, providing solutions that enhance patient care and treatment efficacy.

Sweden

Medical Device Coatings and Drug development to improve outcome of kidney transplantation. 

Corline Biomedical

Company Details